HROW vs TEVA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
HROW · Harrow$30.41 ▼ 5.35%
TEVA · Teva Pharmaceutical Industries$39.23 ▲ 1.79%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- HROW -22.0%
- TEVA +58.4%
Head to head
| Metric | HROW | TEVA |
|---|---|---|
| Price | $30.41 | $39.23 |
| Change today | ▼ 5.35% | ▲ 1.79% |
| Market cap | $1.14B | $45.77B |
| Return, 3 months | -23.6% | +6.2% |
| Return, year to date | -37.9% | +25.7% |
| Return, 1 year | -21.8% | +62.0% |
| P/E (TTM) | – | 91.2 |
| P/B | 39.1 | 5.7 |
| P/E percentile vs own 5y | 38th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +38.6% | -1.9% |
| Net profit growth (YoY) | +856.6% | -46.1% |
| Gross margin | 73.5% | 53.5% |
| Operating margin | -2.0% | 19.2% |
| Net margin | -9.4% | 2.9% |
| Return on equity | -74.8% | 6.6% |
| Analyst target vs. price | +109.4% | +31.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 53 | 40 |
| 30-day volatility | 67.6% | 38.6% |
| Max drawdown, 1 year | -52.5% | -21.8% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TEVA is the largest of the group by market value.
- TEVA has returned the most over the past year.
- HROW is growing revenue fastest.
- TEVA keeps the most profit per dollar of sales.
- TEVA has been the calmest stock over the last 30 days.